Niell H B, Neely C L, Palmieri G M
Cancer. 1981 Aug 1;48(3):783-7. doi: 10.1002/1097-0142(19810801)48:3<783::aid-cncr2820480321>3.0.co;2-h.
The simple postabsorptive urine hydroxyproline (Spot-HYPRO) with dialyzable and non-dialyzable (ND) fractions was measured in 28 patients with multiple myeloma. Myeloma patients with bone disease had higher total Spot-HYPRO and dialyzable fractions (P less than 0.001) than myeloma patients without bone disease or controls. The ND fraction of the Spot-HYPRO was elevated in myeloma patients with renal disease as compared with myeloma patients without renal disease and controls (P less than 0.01). Follow-up studies of ten myeloma patients demonstrated a close correlation between Spot-HYPRO and the dialyzable fraction and the evolution of bone disease. The Spot-HYPRO and its dialyzable fraction constitute a simple, inexpensive, and accurate test for the diagnosis and follow-up of the skeletal disease in patients with multiple myeloma.
对28例多发性骨髓瘤患者测定了含可透析和不可透析（ND）组分的单纯吸收后尿羟脯氨酸（即时尿羟脯氨酸）。患有骨病的骨髓瘤患者的总即时尿羟脯氨酸和可透析组分高于无骨病的骨髓瘤患者或对照组（P<0.001）。与无肾脏疾病的骨髓瘤患者和对照组相比，患有肾脏疾病的骨髓瘤患者的即时尿羟脯氨酸的ND组分升高（P<0.01）。对10例骨髓瘤患者的随访研究表明，即时尿羟脯氨酸与可透析组分以及骨病进展之间密切相关。即时尿羟脯氨酸及其可透析组分构成了一种用于多发性骨髓瘤患者骨骼疾病诊断和随访的简单、廉价且准确的检测方法。
